Strongbridge Biopharma Stock Forecast, Price & News

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SBBP shares have increased by 19.0% and is now trading at $2.76.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Strongbridge Biopharma or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Strongbridge Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Strongbridge Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Strongbridge Biopharma.

Strongbridge Biopharma plc (NASDAQ:SBBP) released its quarterly earnings data on Thursday, October, 29th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.08. The biotechnology company had revenue of $8.07 million for the quarter, compared to analysts' expectations of $7.23 million. Strongbridge Biopharma had a negative net margin of 205.02% and a negative return on equity of 80.86%.
View Strongbridge Biopharma's earnings history.

Strongbridge Biopharma updated its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28-29 million, compared to the consensus revenue estimate of $27.8 million.

4 equities research analysts have issued 1 year price targets for Strongbridge Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Strongbridge Biopharma's share price to reach $7.13 in the next twelve months. This suggests a possible upside of 158.2% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma.

Some companies that are related to Strongbridge Biopharma include Five Prime Therapeutics (FPRX), Omeros (OMER), MannKind (MNKD), Kadmon (KDMN), Kadmon (KDMN), Albireo Pharma (ALBO), VBI Vaccines (VBIV), Spectrum Pharmaceuticals (SPPI), Gossamer Bio (GOSS), Vanda Pharmaceuticals (VNDA), AnaptysBio (ANAB), Emisphere Technologies (EMIS), Collegium Pharmaceutical (COLL), Akouos (AKUS) and Nabriva Therapeutics (NBRV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Caxton Corp (12.03%), Stonepine Capital Management LLC (2.86%), BlackRock Inc. (2.84%), Morgan Stanley (2.82%), Granite Point Capital Management L.P. (1.64%) and State Street Corp (1.08%). Company insiders that own Strongbridge Biopharma stock include Associates LLC Cdk and David N Gill.
View institutional ownership trends for Strongbridge Biopharma.

SBBP stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Acadian Asset Management LLC, BlackRock Inc., First Quadrant L P CA, and State Street Corp.
View insider buying and selling activity for Strongbridge Biopharma.

SBBP stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Caxton Corp, Granite Point Capital Management L.P., Morgan Stanley, ExodusPoint Capital Management LP, Worth Venture Partners LLC, Wells Fargo & Company MN, and Jane Street Group LLC. Company insiders that have bought Strongbridge Biopharma stock in the last two years include Associates LLC Cdk, and David N Gill.
View insider buying and selling activity for Strongbridge Biopharma.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $2.76.

Strongbridge Biopharma has a market capitalization of $185.59 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Strongbridge Biopharma employs 71 workers across the globe.

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]